NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

PR Newswire associated2

PR Newswire associated3

Tags

NeoMab-Antibody

More Like This

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

PR Newswire associated0

genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure